A multicenter prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung cancer

被引：0

作者：

Iwama, E. ^{[1
]}

Sakai, K. ^{[2
]}

Azuma, K. ^{[3
]}

Nosaki, K. ^{[4
]}

Harada, D. ^{[5
]}

Hotta, K. ^{[6
]}

Ohyanagi, F. ^{[7
]}

Kurata, T. ^{[8
]}

Akamatsu, H. ^{[9
]}

Goto, K. ^{[10
]}

Fukuhara, T. ^{[11
]}

Nakanishi, Y. ^{[1
]}

Nishio, K. ^{[2
]}

Okamoto, I. ^{[1
]}

机构：

[1] Kyushu Univ, Res Inst Dis Chest, Fukuoka 812, Japan

[2] Kinki Univ, Sch Med, Dept Genome Biol, Osakasayama, Japan

[3] Kurume Univ, Sch Med, Dept Internal Med, Div Respirol Neurol & Rheumatol, Fukuoka, Japan

[4] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Fukuoka, Japan

[5] Shikoku Canc Ctr, Dept Thorac Oncol, Matsuyama, Ehime, Japan

[6] Okayama Univ Hosp, Resp Med, Okayama, Japan

[7] Canc Inst Hosp JFCR, Dept Thorac Med Oncol, Tokyo, Japan

[8] Kansai Med Univ, Dept Internal Med 1, Osaka, Japan

[9] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan

[10] Natl Canc Ctr Hosp East, Thorac Oncol, Kashiwa, Chiba, Japan

[11] Miyagi Canc Ctr, Dept Resp Med, Sendai, Miyagi, Japan

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

484PD

引用

页码：148 / 149

页数：2

共 50 条

[21] Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population
Noorwati SUTANDYO
Arif HANAFI
Mulawarman JAYUSMAN
中国肺癌杂志, 2019, (09) : 562 - 567
[22] Monitoring therapy with erlotinib and afatinib in a patient with advanced non-small cell lung cancer and activating EGFR-mutation by sequential FLT-PET
Scheffler, M.
Kobe, C.
Zander, T.
Nogova, L.
Neumaier, B.
Dietlein, M.
Wolf, J.
ONKOLOGIE, 2011, 34 : 154 - 154
[23] Cardiovascular events in eGFR-mutation non-small-cell lung cancer patients on osimertinib
Mensah, Samuel Akaakole
Ahmad, Syed
Alruwaili, Waleed
Raval, Rutu
Gonuguntla, Karthik
Patel, Brijesh
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024,
[24] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
Igawa, Satoshi
Ono, Taihei
Kasajima, Masashi
Kusuhara, Seiichiro
Otani, Sakiko
Fukui, Tomoya
Yokoba, Masanori
Kubota, Masaru
Katagiri, Masato
Mitsufuji, Hisashi
Sasaki, Jiichiro
Naoki, Katsuhiko
INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1906 - 1914
[25] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
Satoshi Igawa
Taihei Ono
Masashi Kasajima
Seiichiro Kusuhara
Sakiko Otani
Tomoya Fukui
Masanori Yokoba
Masaru Kubota
Masato Katagiri
Hisashi Mitsufuji
Jiichiro Sasaki
Katsuhiko Naoki
Investigational New Drugs, 2020, 38 : 1906 - 1914
[26] Epidermal growth factor receptor (EGFR)-mediated adverse events (AEs) in patients (pts) with EGFR mutation positive (EGFR M plus ) non-small cell lung cancer treated with afatinib
Yang, J. Chih-Hsin
Sequist, L.
O'Byrne, K.
Schuler, M.
Mok, T.
Geater, S.
Massey, D.
O'Brien, D.
Zazulina, V.
Wu, Y. L.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S190 - S190
[27] A prospective observational multicenter cfDNA study in EGFR-mutated non-small cell lung cancer treated with osimertinib
Osuga, Mitsuo
Tamiya, Akihiro
Mizumori, Yasuyuki
Isa, Shunichi
Fujita, Yuka
Kozuki, Toshiyuki
Shinohara, Tsutomu
Yanai, Hidetoshi
Nakatomi, Katsumi
Oki, Masahide
Mori, Masahide
Kuwako, Tomohito
Yamazaki, Koji
Tamura, Atsuhisa
Ando, Masahiko
Koh, Yasuhiro
CANCER SCIENCE, 2024, 115 : 845 - 845
[28] Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer
Lilenbaum, Rogerio A.
Horn, Leora A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (5.5): : 672 - 674
[29] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
Alsharedi, M.
Bukamur, H.
Elhamdani, A.
DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
[30] Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer
Meinrenken, Susanne
PNEUMOLOGIE, 2018, 72 (04): : 246 - 246

← 1 2 3 4 5 →